Abstract 1084
Background
Immune checkpoint inhibitors (ICI) have been demonstrated to improve overall survival (OS) in several cancer types. Atypical patterns of response have been reported including durable responses, pseudoprogression and hyperprogression. We evaluated the occurrence of dissociated response (DR) on immunotherapy.
Methods
We retrieved all patients treated at the Curie Institute with an ICI either alone or in combination with another ICI in the frame of a clinical trial. Patients had to have a baseline CT-scan and at least one follow-up CT-scan, and at least two target lesions (TLs). There was no selection on tumor type. All TLs on CT-scans were assessed by two independent readers according to RECIST 1.1. Three types of DR were evaluated: 1) one TL in partial or complete response (CR/PR) and one progressive TL (DR1), 2) one stable TL and one progressive TL (DR2), and 3) one TL in CR/PR and one stable TL (DR3). Finally, we evaluated the impact of previous radiotherapy and biopsy on TLs on the occurrence of DRs.
Results
1,246 measures of 272 TLs were performed in the 100 patients who met our inclusion criteria. The median number of TLs per patient was 3 [range: 2-5]. 49 out of the 272 TLs (18%) had received prior radiotherapy, and 38 (14%) had been biopsied. Median progression-free survival (PFS) was 3.8 months. Median OS was 13.4 months. Best overall response per patient was a PR/CR in 22%, stable disease (SD) in 33% and progressive disease (PD) in 45%. Best overall response on 272 TLs was a PR/CR in 52 TLs (19%), SD in 142 TLs (52%) and PD in 78 TLs (29%). DR1 were observed in 8% of patients, whereas DR2 and DR3 were observed in 44% and 10% of patients, respectively. While prior irradiation on TLs did not correlate with the occurrence of DRs, DRs were more common when one TL was biopsied ORa = 2.22 (1.28, 3.86) (p = 0.004).
Conclusions
DR with a responding TL and a progressive TL according to RECIST1.1 was observed in 8% of patients. While prior irradiation on TLs did not correlate with the occurrence of DRs, DRs were more common when one TL was biopsied.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Loirat: Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Novartis; Honoraria (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Pfizer. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck; Advisory / Consultancy: Serono; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Nanobiotix; Advisory / Consultancy: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
1885 - Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: an open label, non randomized study
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
5259 - Integrative RNAseq and Target panel sequencing reveals common and distinct innate and adaptive resistance mechanisms to BRAF inhibitors
Presenter: Phil Cheng
Session: Poster Display session 3
Resources:
Abstract
5619 - Effective treatment with T-VEC monotherapy in Stage IIIB/C-IVM1a Melanoma of the Head & Neck Region
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
5666 - Re-introduction of T-VEC Monotherapy in Recurrent Stage IIIB/C-IVM1a melanoma is effective
Presenter: Viola Franke
Session: Poster Display session 3
Resources:
Abstract
4117 - Efficacy of talimogene laherparepvec (T-VEC) in melanoma patients (pts) with locoregional (LR) recurrence, including in-transit metastases (ITM): subgroup analysis of the phase 3 OPTiM study
Presenter: Mark Middleton
Session: Poster Display session 3
Resources:
Abstract
5303 - Real Life Use of Talimogene Laherparepvec in Melanoma in Centers in Austria and Switzeland
Presenter: Christoph Hoeller
Session: Poster Display session 3
Resources:
Abstract
4130 - Outcomes of advanced melanoma patients who discontinued pembrolizumab (pembro) after complete response (CR) in the French early access program (EAP)
Presenter: Philippe Saiag
Session: Poster Display session 3
Resources:
Abstract
2050 - Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Presenter: Sarah Knispel
Session: Poster Display session 3
Resources:
Abstract
1618 - Comparative-Effectiveness of Pembrolizumab vs. Nivolumab for Patients with Metastatic Melanoma
Presenter: Justin Moser
Session: Poster Display session 3
Resources:
Abstract
3556 - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: a network meta-analysis
Presenter: Peter Mohr
Session: Poster Display session 3
Resources:
Abstract